HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
NEWS CRUNCH
AbbVie opens biologics manufacturing facility in Singapore

At the official opening ceremony of AbbVie Biologics Manufacturing Facility (Left to Right): Marc O'Donoghue, Site Director of AbbVie Operations Singapore; Dr Beh Swan Gin, Chairman, Singapore Economic Development Board; Mr. S Iswaran, Minister of Trade & Industry (Industry); Rick Gonzalez, Chairman of the Board and Chief Executive Officer of AbbVie; Azita Saleki-Gerhardt, Senior Vice President and President of AbbVie Operations and Daniella Ottini, Vice-President of Manufacturing Operations Biologics

AbbVie, a global research and development-based biopharmaceutical company, opened its Biologics Manufacturing Facility, expanding its capabilities to include biological products in addition to its existing small molecule active pharmaceutical ingredient (API) facility.

The combined facilities support the company's global manufacturing operations to address AbbVie's pipeline in the therapeutic areas of immunology and oncology.


AbbVie Global Manufacturing Facility, Singapore

"Today's milestone represents our dedication to providing life-changing treatments for patients. Just as we are focused on uncovering therapies to address unmet patient needs, equally important is enhancing our capabilities to ensure supply of these medicines for our patients," said Azita Saleki-Gerhardt, Ph.D., senior vice president, operations, AbbVie.

Located in Tuas Biomedical Park, this facility is expected to employ about 250 people across different roles such as supply chain management, technical operations and manufacturing.

"We are delighted that AbbVie has chosen Singapore as the location for the establishment of their first biologics manufacturing facility in Asia. AbbVie's latest investment is testament to Singapore's strong track record of high quality biopharmaceutical manufacturing. We continue to see strong growth in this industry sector, and EDB remains committed to invest in areas such as talent, technology and infrastructure to support this growth." said Ms. Ho Weng Si, Director, Biomedical Sciences, Singapore Economic Development Board (EDB). Mr Rick Gonzalez, chairman of the board and CEO of AbbVie added that the biologics manufacturing facility would not have been possible without the tremendous support from the Singapore Government and EDB.

The Singapore site is the only one in the AbbVie global manufacturing network to house both API and biologics manufacturing capabilities. The local API facility started operations for commercial supply earlier this year. Singapore joins 12 other sites across the US, Europe and Puerto Rico in AbbVie's global manufacturing network.

NEWS CRUNCH  
news Not Science Fiction anymore — the emergence of AI and Robotics in Healthcare
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy